If the combination cannot be avoided, monitor closely for adverse effects. Monitor closely.Miconazole (Oral): May enhance the hypoglycemic effect of Sulfonylureas. Dose titration: Increase dose in increments of no more than glipizide 5 mg/metformin 500 mg/day. Management: Avoid use of MATE substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the MATE substrate and consider a reduced dose of the MATE substrate according to that substrate's labeling.Tafenoquine: May increase the serum concentration of OCT2 Substrates. Maximum: Glipizide 20 mg/metformin 2,000 mg/day in divided doses. Management: Consider alternatives to this combination or use of lower metformin doses. Insulin secretion and sensitivity may be partially or completely restored after these procedures (gastric bypass is most effective, followed by sleeve and finally band) (Korner 2009; Peterli 2012). First-phase insulin secretion and hepatic insulin sensitivity have been shown to be significantly improved in the immediate days after gastric bypass and sleeve gastrectomy. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.RaNITIdine (Withdrawn from US Market): May increase the serum concentration of Sulfonylureas.Ranolazine: May increase the serum concentration of MetFORMIN. In addition, each tablet contains the following inactive ingredients: microcrystalline In a scientific statement from the American Heart Association, metformin has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]). Glipizide and Metformin (Professional Patient Advice) - Drugs.com Specifically, the risk of developing lactic acidosis may be increased.Cephalexin: May increase the serum concentration of MetFORMIN.Chloramphenicol (Systemic): May increase the serum concentration of Sulfonylureas.Cimetidine: May increase the serum concentration of MetFORMIN. Glipizide and metformin is a combination of two oral diabetes medicines that help control blood sugar levels. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms, such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Vitamin K Antagonists may enhance the hypoglycemic effect of MetFORMIN. Alcohol (Ethyl): May enhance the adverse/toxic effect of MetFORMIN. Refer to the full drug interaction monograph content for details.Isavuconazonium Sulfate: May increase the serum concentration of MetFORMIN.LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: Consider sulfonylurea dose adjustments in patients taking thiazolidinediones and monitor for hypoglycemia.Topiramate: May enhance the adverse/toxic effect of MetFORMIN.Trimethoprim: May increase the serum concentration of MetFORMIN.Trospium: MetFORMIN may decrease the serum concentration of Trospium. Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN.
Specifically, alcohol may potentiate the risk of lactic acidosisAlpelisib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).Alpha-Glucosidase Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Follow your doctor's instructions very closely.Store at room temperature away from moisture and heat.Take your dose as soon as you can, but only if you are getting ready to eat a meal. Carefully weigh the risk of metformin toxicities (including lactic acidosis) against the benefit of combining dolutegravir with metformin.Elexacaftor, Tezacaftor, and Ivacaftor: May increase the serum concentration of GlipiZIDE.Erdafitinib: May increase the serum concentration of OCT2 Substrates.Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas.
Use of metformin in patients with HF may be associated with reduced mortality and reduction in hospital readmission for HF (Crowley 2017; Eurich 2013).• Hepatic impairment: The manufacturer recommends to generally avoid use in patients with hepatic impairment due to potential for lactic acidosis.
There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). Management: Limit the metformin dose to a maximum of 1,700 mg per day when used together with ranolazine 1,000 mg twice daily. Dalfampridine may increase the serum concentration of MetFORMIN. Management: Consider a decrease in sulfonylurea dose when initiating therapy with an alpha-glucosidase inhibitor and monitor patients for hypoglycemia.Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). Glipizide / metformin systemic 2.5 mg / 500 mg (cor 168)